Author:
Chaurawal Nishtha,Misra Charu,Abul Barkat Harshita,Jatyan Reena,Chitkara Deepak,Barkat Md. Abul,Sharma Teenu,Singh Bhupinder,Raza Kaisar
Abstract
AbstractSorafenib tosylate (SFB) is a multikinase inhibitor that inhibits tumour growth and proliferation for the management of breast cancer but is also associated with issues like toxicity and drug resistance. Also, being a biopharmaceutical class II (BCS II) drug, its oral bioavailability is the other challenge. Henceforth, this report intended to encapsulate SFB into a biocompatible carrier with biodegradable components, i.e., phospholipid. The microemulsion of the SFB was prepared and characterized for the surface charge, morphology, micromeritics and drug release studies. The cell viability assay was performed on 4T1 cell lines and inferred that the IC50 value of sorafenib-loaded microemulsion (SFB-loaded ME) was enhanced compared to the naïve SFB at the concentrations of about 0.75 µM. More drug was available for the pharmacological response, as the protein binding was notably decreased, and the drug from the developed carriers was released in a controlled manner. Furthermore, the pharmacokinetic studies established that the developed nanocarrier was suitable for the oral administration of a drug by substantially enhancing the bioavailability of the drug to that of the free SFB. The results bring forth the preliminary evidence for the future scope of SFB as a successful therapeutic entity in its nano-form for effective and safer cancer chemotherapy via the oral route.
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 71, 209–249 (2021).
2. Fahad Ullah, M. Breast cancer: Current perspectives on the disease status. Adv. Exp. Med. Biol. 1152, 51–64 (2019).
3. Salzman, B., Collins, E. & Hersh, L. Common breast problems. Am. Fam. Physician 99, 505-514A (2019).
4. O’Brien, Z. & Moghaddam, M. F. A systematic analysis of physicochemical and ADME properties of all small molecule kinase inhibitors approved by US FDA from January 2001 to October 2015. Curr. Med. Chem. 24, 3159–3184 (2017).
5. Abdelgalil, A. A., Alkahtani, H. M. & Al-Jenoobi, F. I. Sorafenib. Profiles Drug Subst. Excipients Relat. Methodol. 44, 239–266 (2019).
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献